Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tulisokibart induction therapy in moderately to severely active ulcerative colitis
2023-509741-12-00Phase 2Completed
- Sponsor
- Prometheus Biosciences
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing tulisokibart with placebo (2 arms). Primary endpoints: Safety and tolerability and Clinical remission at Week 12. Started Sep 2021; status: completed.
02
Drugs
tulisokibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-509741-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509741-12-00.